In this episode of Drug Digest, experts navigate biopharma’s evolving landscape for strategic partnerships and AI innovation, which are driving market expansion and novel therapeutic modalities. The discussion centers around the optimization of biopharmaceutical manufacturing and supply chain efficiency through the mastering of AI capabilities, data integration, and critical validation challenges.
Register Free: https://www.pharmtech.com/pt_w/strategic-alliances
Event Overview:
The biopharma industry is actively navigating an evolving landscape through strategic partnerships and advanced technology integration. Collaborations are crucial for market expansion, while some companies are leveraging artificial intelligence (AI) for the discovery of novel therapeutic modalities and for manufacturing efficiency. Experts evaluate partners for their AI capabilities, focusing on data integration and validation challenges. Manufacturing, licensing agreements, and supply chain strategies are also paramount. This episode of Drug Digest will explore these trends and how partnering can lead to success in bringing new biopharmaceutical modalities to market.
Interviews featuring:
- Jason Brock, CEO and Co-Founder, CTMC
- Sigma Mostafa, Chief Scientific Officer, KBI Biopharma
- Cory Smith, Senior Product Manager, Nucleic Acid Services, TriLink Biotechnologies
This episode of Drug Digest is sponsored by:
- Adare
- BioVectra
- Eppendorf
- Labvantage
- PDA
Key Learning Objectives:
- Analyze strategic partnerships and licensing in biopharma expansion
- Evaluate the role and challenges of advanced technologies in drug discovery
- Compare and contrast biopharma manufacturing and supply chain strategies
- Discuss strategic motivations and integration challenges in biopharma M&A and novel therapies
Who Should Attend:
- Biotechnology and Pharmaceutical Technology Experts
- Biopharmaceutical Business Development and Strategy Leaders
- Manufacturing and Supply Chain Executives
- R&D Directors and Scientists
- Investors and Analysts in the Life Sciences Sector
Speakers:
Jason Brock
CEO and Co-Founder
CTMC
Jason Bock is the chief executive officer and co-founder of CTMC. He has 20+ years of innovative biologics development and commercialization experience. Based in Houston, Texas, CTMC was conceived to accelerate patient access to impactful cell therapies by bridging cell therapy development and manufacturing with MD Anderson’s clinical trial capabilities. Bock previously held leadership positions at MD Anderson, Teva Pharmaceuticals, CoGenesys, and Human Genome Sciences.
Sigma Mostafa, PhD
Chief Scientific Officer
KBI Biopharma
Sigma Mostafa, PhD, is chief scientific officer at KBI Biopharma, where she oversees Analytical Services, Process Development, and Cell Line Development. Over her 13-year tenure, she has driven the company’s rapid growth, building KBI’s North Carolina operations into a world-class contract development and manufacturing organization with advanced automation and scaling its development programs tenfold. Previously, she served as senior vice-president and site head, leading KBI’s largest site through unprecedented expansion and a successful FDA pre-licensure inspection.
Cory Smith
Senior Product Manager
Nucleic Acid Services
TriLink Biotechnologies
Cory Smith is senior product manager, Nucleic Acid Services, at TriLink Biotechnologies. He manages the contract development and manufacturing organization service business at the company, where he focuses on good manufacturing practice manufacturing to support clinical and commercial-stage therapeutics. Smith has spent 10 years in the RNA field on both the drug developer and contract manufacturing side of operations. He is dedicated to helping researchers and drug developers find rapid solutions to bring their drug candidates from discovery to commercialization.
Register Free: https://www.pharmtech.com/pt_w/strategic-alliances
